

UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS

_____	)	
IN RE PHARMACEUTICAL INDUSTRY	)	
AVERAGE WHOLESALE PRICE	)	
LITIGATION	)	MDL NO. 1456
_____	)	
THIS DOCUMENT RELATES TO:	)	MASTER CASE NO. 01-cv-12257-PBS
TRACK TWO SETTLEMENT	)	
_____	)	

**MEMORANDUM AND ORDER**

August 30, 2011

Saris, U.S.D.J.

This massive, decade-long, nationwide, multi-district class action against thirteen pharmaceutical companies (and related entities) involves the pricing of pharmaceutical drugs reimbursed by Medicare, private insurers, and patients making coinsurance payments based on average wholesale price ("AWP") between 1991 and 2005. For the most part, the drugs at issue are administered by doctors for the treatment of cancer and other serious ailments. Some are branded single source drugs; others are multi-source drugs which are branded and generic. This is an old, sick, and dying class.

Class Counsel now seek final approval from the Court of the modified Track Two Settlement (Docket No. 5133) with the Track

Two defendants.<sup>1</sup> As part of that process, Class Counsel has moved to add several new consumer class representatives. (Docket No. 7572.)

After a review of the record, the Court **ALLOWS** the Motion to Add Individual Plaintiffs as Class Representatives for Subclass 1 of the Track Two Settlement.

### **DISCUSSION**

The "Medicare Part B Co-Payment Class" (Subclass 1) proposed here is defined as:

All natural persons in the United States who, from January 1, 1991 through January 1, 2005, made, or incurred an obligation to make, any portion of a Medicare Part B co-payment for a Class Drug manufactured, marketed, sold or distributed by a Released Company.

(Proposed Settlement Agreement at 5.) The current class representatives for Class 1 are four nonprofit organizations: Vermont Public Interest Research Group, Wisconsin Citizen Action, New York Statewide Senior Action Council, and Citizen Action of New York.<sup>2</sup> In addition, Muriel Tonacchio, as executor of her

---

<sup>1</sup> The Track Two defendants are Abbott Laboratories, Amgen Inc., Aventis Pharmaceuticals Inc., Hoechst Marion Roussel, Baxter Healthcare Corp., Baxter International Inc., Bayer Corporation, Dey, Inc., Fujisawa Healthcare, Inc., Fujisawa USA, Inc., Immunex Corporation, Pharmacia Corporation, Pharmacia & Upjohn LLC (f/k/a Pharmacia & Upjohn, Inc.), Sicor, Inc., Gensia, Inc., Gensia Sicor Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc., and ZLB Behring, L.L.C. (Proposed Settlement Agreement, Docket No. 5133.)

<sup>2</sup> Health Care for All was also a class representative, but has moved to withdraw. (Docket No. 7503.) Magistrate Judge

mother's estate, was added as a Class 1 representative on July 21, 2008.<sup>3</sup> (See also Docket No. 5409.)

Class counsel now seek to add three additional individual class representatives for Class 1: Agnes Swayze, Thomas Trusky and Mariella Laday. Class representatives must have Article III standing and they must satisfy the adequacy and typicality requirements of Rule 23.

**A. Standing**

Article III standing requirements "are expressed in a familiar three-part algorithm: a would-be plaintiff must demonstrate a concrete and particularized injury in fact, a causal connection that permits tracing the claimed injury to the defendant's actions, and a likelihood that prevailing in the action will afford some redress for the injury." Me. People's Alliance & Natural Res. Def. Council v. Mallinckrodt, Inc., 471 F.3d 277, 283 (1st Cir. 2006) (citing Lujan v. Defenders of Wildlife, 504 U.S. 555, 560-61 (1992)). In order to show that they have standing in this case, subclass 1 consumers must show that they paid for a Track Two drug based on AWP. See In re Pharm. Indus. Average Wholesale Price Litig., 230 F.R.D. 61, 81

---

Bowler issued a Report and Recommendation on the motion (Docket No. 7591) recommending that the motion be allowed. No objections have been filed.

<sup>3</sup> Ms. Tonacchio's mother, Wilma Mort, took the following drugs: Epogen (Amgen), Anzemet (Aventis), Accuneb (Dey), and Ipratropium Bromide (Dey).

(D. Mass. 2005).

In addition, this Court has previously held, in the context of certification of a class for purposes of litigation, that there must be at least one "individual class representative with standing to sue each defendant" - or as class counsel have said, a one plaintiff-one defendant rule. In re Average Wholesale Price Litig., 230 F.R.D. 61, 80 (D. Mass. 2005).

The Court addresses the Article III standing of each newly proposed class representative individually. Among the claims pursued by Ms. Swayze, Ms. Laday, Mr. Trusky and Ms. Tonacchio, the one plaintiff-one defendant requirement is satisfied.

1. Agnes Swayze

The Court finds that Agnes Swayze received injections of the drugs Anzemet Dextrose, Dexamethasone Sodium Phosphate, Heparin sodium, and Neupogen as part of chemotherapy treatments in 2002 and 2003, and that she made out-of-pocket copayments for administrations of those drugs. See Swayze Aff. ¶ 5, May 30, 2011. Ms. Swayze has provided billing records from the Valley Tumor Medical Group and the Lancaster Community Hospital as evidence that she received injections of these medications in 2002 and 2003. Swayze Aff., Ex. 1. In addition, Ms. Swayze's claim form for this Track Two settlement shows that she received injections of the drugs listed above, and lists her Medicare copay obligation for each administration. Id., Ex. 2. Finally, Ms. Swayze has provided a check register that shows payments made

to Lancaster Community Hospital for a visit on April 28, 2000. Ms. Swayze's Track Two claim form, populated by information received by the Centers for Medicaid and Medicare Services, indicates that she received an injection of sodium chloride on April 28, 2000. See Swayze Supp. Aff., Exs. 1-2, June 23, 2011.

Ms. Swayze's billing records from the Valley Tumor Group and Lancaster Community Hospital list a patient amount as zero, which might suggest that she did not make co-payments for Track Two drugs. Ms. Swayze said under oath that she made out-of-pocket payments. Because Ms. Swayze was a Medicare beneficiary during the relevant time period, we know that she was responsible for 20% of all drug costs, with Medicare covering 80%. Ms. Swayze has stated under oath that at no time did she carry supplemental insurance. See Swayze Aff. ¶ 8. The billing records support this statement: In the column for charges to a secondary insurance, there is no amount listed. Id., Ex. 1. Moreover, in a report from Ms. Swayze's physician, Dr. Shamasunder, he notes that the "patient does have only Medicare and one of our nurses talked to her about the cost of medication." Hr'g Ex. 3, June 13, 2011. As such, Ms. Swayze's statement that she made payments is likely true.

Class counsel originally stated that Ms. Swayze had been administered Epogen, an Amgen drug. However, records appear to show that she was in fact administered Procrit, which is the medical-equivalent of Epogen manufactured by Johnson and Johnson,

which is not a Track Two defendant. Class counsel have acknowledged this error. Nonetheless, Ms. Swayze is still an appropriate Amgen class representative because there is evidence that she received injections of Neupogen, another Amgen drug.

Accordingly, the Court finds that Agnes Swayze has standing to be a Track Two consumer class 1 representative for the following defendants: Abbott Laboratories, Amgen, Aventis, Baxter, and Watson.

2. Mariella Laday

The Court finds that Mariella Laday received injections of the drugs Ketorolac, Methotrexate Sodium, Sodium Chloride, Gammagard, Gamimune, Accuneb, Adenoisine, Aristospan, and Lyphocin from 2000 to 2004, and that she made out-of-pocket copayments for administrations of those drugs. See Laday Aff. ¶¶ 2, 4, May 24, 2011. Ms. Laday's claim form for this Track Two settlement shows that she received injections of the drugs listed above, and lists her Medicare copay obligation for each administration. Id., Ex. 1. In addition, Ms. Laday provided more than 200 canceled checks that show payments made to various doctors, pharmacies, hospitals, and recovery centers during the relevant time period. See Berman Decl., Ex. 5, June 24, 2011. While it is not possible to match the canceled checks exactly to corresponding administrations of Track Two drugs, Ms. Laday's payment records make it clear that she was paying a substantial amount of money out-of-pocket for medical care during the

relevant time period. This supports Ms. Laday's statement that she did make percentage co-payments for Track Two drug administrations that were not reimbursed by any insurer. Laday Aff. ¶ 4.

Ms. Laday was administered Track Two drugs at Piedmont Hospital in Atlanta, Georgia, but does not have standing under the Georgia Consumer Protection Statute because it does not permit class actions. See In re Pharm. Indus. Average Wholesale Price Litig., 233 F.R.D. 229, 230 (D. Mass. 2006). Ms. Laday does, however, have statutory standing under the RICO statute. The Track Two settlement also resolves plaintiffs' RICO claims, and so there are no standing impediments to Ms. Laday's participation as a class representative.

Accordingly, Ms. Laday has standing to be a Track Two consumer class 1 representative for the following defendants: Abbott Laboratories, Baxter, Bayer, Dey, and Fujisawa.

### 3. Thomas Trusky

Thomas Trusky has been proposed as a new class representative as the executor of Theresa Trusky's estate. Trusky Aff. ¶ 1, June 1, 2011. The Court finds that Theresa Trusky received injections of the drugs Adenoisine, Alcohol injection, Mannitol, Sodium chloride, Epogen, Neulasta, Cisplatin, Doxorubicin, Dexamethosone sodium phosphate, and Etoposide in 2003 and 2004, and that she made out-of-pocket copayments for administrations of those drugs. See Id. ¶¶ 3-4;

id., Ex. 1. Mr. Trusky's claim form (issued for his wife) for this Track Two settlement shows that Theresa Trusky received injections of the drugs listed above, and lists her Medicare copay obligation for each administration. Id., Ex. 1. Mr. Trusky also provided several Medicare records for "Outpatient facility claims," which shows that Theresa Trusky made out-of-pocket credit card payments in 2004 for Neulasta and Doxorubicin. Id., Ex. 2. There are also credit card receipts showing payments made to Marian Community Hospital in Carbondale, PA that correspond with the out-of-pocket payments shown on the Medicare record. Id. Finally, Mr. Trusky provided a credit card bill from 2003 showing payments made to Marian Community Hospital. One of these payments corresponds to a co-payment for an Epogen administration listed on the Track Two settlement claim form. See Trusky Supp. Aff., Ex. 1, June 23, 2011.

During the relevant time period, Theresa Trusky did carry supplemental insurance. However, each year she had to reach a \$4,000 out-of-pocket deductible before the supplemental insurance provided coverage. Trusky Aff. ¶ 3. Mr. Trusky states that due to the high \$4,000 deductible, he is certain that he and his wife paid for Track Two drugs out of pocket during 2003. Trusky Supp. Aff. ¶ 9. This statement is supported by the credit card statement from 2003.

Accordingly, Mr. Trusky has standing to be a Track Two consumer class 1 representative for the following defendants:



Abbott Laboratories, Amgen, Baxter, Fujisawa, Gensia Sicor, Pharmacia, and Watson.

4. Muriel Tonacchio

The Court already added Ms. Tonacchio as a class representative for this settlement in 2008. However, for purposes of Rule 23(e) the Court must nonetheless examine whether she is a typical and adequate class representative. Such an analysis also requires an examination of Article III standing.

Muriel Tonacchio is the executor of her mother, Wilma Mort's, estate. The Court finds that Wilma Mort received injections of the drugs Epogen, Anzemet, Accuneb, and Ipratropium bromide in 2003 and 2004, and that she made out-of-pocket copayments for administrations of those drugs in 2003. See Tonacchio Aff. ¶¶ 2-3. Ms. Mort did carry supplemental insurance during the relevant time period, provided by National Steel Workers insurance. Id. However, the supplemental insurance did not cover all charges for drugs administered in Ms. Mort's chemotherapy treatment. Id.

Ms. Tonacchio has provided medical records showing charges for an administration of Anzemet in 2003. Id., Ex. A. Ms. Tonacchio stated under oath that she spoke to a representative of the Weirton Medical Center, where her mother received treatments, who informed her that Ms. Mort was required to pay for Anzemet in 2003 because her supplemental insurance declined coverage for Ms. Mort's 20% copay obligation. Id. ¶ 4.

Accordingly, Ms. Tonacchio has standing to be a Track Two consumer class 1 representative for the following defendants: Amgen, Aventis, and Dey.

**B. Typicality**

Pursuant to Federal Rule of Civil Procedure 23(a), the Court must also determine whether the proposed individual class representatives meet the Rule 23(a) requirements of typicality and adequacy. Rule 23(a)(3) requires that "claims or defenses of the representative parties [be] typical of the claims or defenses of the class."

Typicality determines whether a sufficient relationship exists between the injury to the named plaintiff and the conduct affecting the class, so that the court may properly attribute a collective nature to the challenged conduct. In other words, when such a relationship is shown, a plaintiff's injury arises from or is directly related to a wrong to a class, and that wrong includes the wrong to the plaintiff. Thus, a plaintiff's claim is typical if it arises from the same event or practice or course of conduct that gives rise to the claims of other class members, and if his or her claims are based on the same legal theory.

In re Am. Medical Sys., Inc., 75 F.3d 1069, 1082 (6th Cir. 1996) (internal citations omitted); see also 1 Albert Conte & Herbert B. Newberg, Newberg on Class Actions § 3.13 (4th ed. 2002) (the typicality requirement is usually met "when it is alleged that the same unlawful conduct was directed at or affected both the named Plaintiffs and the class sought to be represented").

Based on the findings regarding standing, the Court is able to conclude that the proposed class representatives' claims are

typical of the class. Agnes Swayze, Mariella Laday, Thomas Trusky, and Muriel Tonacchio (or their decedents) paid out-of-pocket to cover a Medicare 20% co-payment for multiple Class Drugs that were reimbursed based on AWP. There is no potential conflict between the proposed representatives' claims and those of the class.

The Court also finds that the proposed class representatives are typical of the class to the extent that they paid for multi-source Track Two drugs. Each of the proposed class representatives, with the exception of Thomas Trusky, paid for at least one single source, Group A drug included in the Track Two settlement. It is exceedingly difficult for class members who paid for multi-source drugs to identify the manufacturer of the specific drug they took, because multi-source, or generic, drugs manufactured by multiple companies share the same "J-code" used for reimbursement purposes. Instead, potential class members are identified and contacted about the settlement using Medicare records from the Centers for Medicare and Medicaid Services that indicate those Medicare beneficiaries who were prescribed drugs with J-Codes matching those of the Class Drugs during the class period. The proposed class representatives are unable to offer evidence that the multi-source drugs they paid for were manufactured by a Track Two defendant, as opposed to a manufacturer that is not a party to this action. However, few if

any class members submitting claims as part of this settlement will be able to identify the manufacturer of their multi-source drugs. Indeed, in structuring the settlement itself, the parties decided to allow class members making claims for multi-source drugs to submit claim forms based on the J-code evidence alone, as opposed to any further documentation that they took a drug manufactured by a defendant. Accordingly, the proposed class representatives who are unable to identify a multi-source manufacturer are in the same shoes as the typical class member.

**C. Adequacy**

Rule 23(a)(4) requires that the representatives "fairly and adequately assert and protect the interests of the class." "The adequacy inquiry . . . serves to uncover conflicts of interest between named parties and the class they seek to represent." Amchem Prods., Inc. v. Windsor, 521 U.S. 591, 626 (1997) (citing Gen. Telephone Co. of Southwest v. Falcon, 457 U.S. 147, 157-58 n.13 (1982)). The adequacy requirement "has two parts. The moving party must show first that the interests of the representative party will not conflict with the interests of any of the class members, and second, that counsel chosen by the representative party is qualified, experienced and able to vigorously conduct the proposed litigation." Andrews v. Bechtel Power Corp., 780 F.2d 124, 130 (1st Cir. 1985).

The Court must determine whether the proposed class

representative can be deemed adequate given that they were proposed after the initial settlement was reached. The late timing of plaintiffs' motion to add is troubling. In general, the Court has wide discretion in allowing a motion to add new class representatives, so long as the proposed representatives have no conflict with the class and are represented by capable counsel. Where replacement of a class representative is necessary, "courts generally allow class counsel time to make reasonable efforts to recruit and identify a new representative." See Manual for Complex Litigation 4th, § 21.26. Such discretion protects the interests of the class as a whole, and this Court, in considering settlement of a class action, has an obligation to protect the absent members of the class. See Grant v. Bethlehem Steel Corp., 823 F.2d 20, 23 (2d Cir. 1987).

When a class representative is added on the eve of a settlement fairness hearing, courts are concerned that the settlement is lawyer-driven, and not based on the class representatives' personal experience and knowledge. The Court has only found one unpublished case involving the addition and/or substitution of class representatives on the eve of a settlement fairness hearing. See, e.g., Curtis-Bauer v. Morgan Stanley & Co., Inc., No. 06-cv-3903-TEH, 2008 WL 7748874 (N.D. Cal. July 7, 2008) (ordering an evidentiary hearing in a case where a new representative was proposed after the settlement was reached and

where no class representative participated in settlement negotiations, because the participation of a class representative during settlement negotiations was important to ensure adequate representation and due process for the class).<sup>4</sup>

However, there is no bright line bar to a late addition of a class representative. In a related context, where a class representative objects to a proposed settlement, district courts have permitted class counsel to withdraw from representing the objector and simultaneously propose a new class representative in order to preserve a settlement the court found to be fair. Heit v. Van Ochten, 126 F. Supp. 2d 487, 494-95 (W.D. Mich. 2001) (citing Laskey v. Int'l Union, United Auto., Aerospace & Agr. Implement Workers of America (UAW), 638 F.2d 954, 957 (6th Cir. 1981); Parker v. Anderson, 667 F.2d 1204, 1211 (5th Cir. 1982)). In addition, some courts have approved class settlements notwithstanding objections from the class representatives. See, e.g., Lazy Oil, Co. v. Witco Corp., 95 F. Supp. 2d 290, 333 (W.D. Pa. 1997), aff'd, 166 F.3d 581 (3d Cir. 1999); In re Airline Ticket Comm'n Antitrust Litig., 953 F. Supp. 280, 282 n.3 (D.

---

<sup>4</sup>The Curtis-Bauer court subsequently allowed a motion to reconsider its opinion requiring an evidentiary hearing after the court reviewed documents in camera that revealed a class representative had, in fact, participated in settlement negotiations. The court ultimately allowed the addition of a new class representative and granted final approval of the settlement. Curtis-Bauer v. Morgan Stanley & Co., Inc., No. 06-cv-3903-TEH, 2008 WL 4667090 (N.D. Cal. Oct. 22, 2008).

Minn. 1997). "Agreement of the named plaintiffs is not essential to approval of a settlement which the trial court finds to be fair and reasonable." Parker, 667 F.2d at 1211 (affirming approval of a class settlement opposed by all but one of the eleven named plaintiffs).

The late timing here does not defeat adequacy because of the unique history of this litigation. Despite the settlement, this Court has held three fairness hearings in which the settlement was substantially re-balanced. Agnes Swayze and Thomas Trusky have each submitted three affidavits over the past several months detailing the understanding of and support for the settlement. Mariella Laday and Muriel Tonacchio have each submitted two affidavits. Each of the proposed representatives has spent significant time with class counsel attempting to find decades-old medical and payment records to prove that they have standing as class representatives. Perhaps most significantly, the Court has recently worked diligently with class counsel, along with counsel for objectors and Track Two defendants, in "rebalancing" the Track Two settlement. There have been three fairness hearings to date. Each of the proposed class representatives has been active in voicing his or her understanding and agreement in each iteration of the process. Their affidavits show that they have spent time and effort in understanding a very complex settlement that required the evaluation and valuation of very complex litigation strategies and claims. Moreover, the consumer

class was represented during settlement negotiations by several organizational representatives whose stated purpose is to protect consumers from drug pricing abuses in the pharmaceutical industry.

Moreover, in a complex case such as this, "a plaintiff need not have expert knowledge of all aspects of the case to qualify as a class representative, and a great deal of reliance upon the expertise of counsel is to be expected." Denney v. Jenkins & Gilchrist, 230 F.R.D. 317, 327 (S.D.N.Y. 2005), aff'd in part and vacated in part on other grounds, 443 F.3d 253 (2d Cir. 2006); see also In re Relafen Antitrust Litig., 231 F.R.D. 52, 69 (D. Mass. 2005) (same). The Third Circuit has described why it is appropriate for class representatives to rely on knowledgeable counsel:

We begin by acknowledging the realities of class suits, a sometimes neglected approach in this field. In a massive class action such as the one at hand, it is counsel for the class who has the laboring oar. The class representatives furnish the factual basis to invoke the jurisdiction of the court and provide the outline of the controversy, but the lawyers shape the claims for adjudication by the compilation of factual and expert testimony and the presentation of statistical and documentary evidence.

Goodman v. Lukens Steel Co., 777 F.2d 113, 124 (3d Cir. 1985), aff'd, 482 U.S. 656 (1987); see also Surowitz v. Hilton Hotels Corp., 383 U.S. 363, 370-74 (1966) (indicating that, in the context of a complex securities litigation, attacks on the adequacy of the class representative based on the



representative's ignorance or credibility are rarely appropriate). In Goodman, the court noted that, where class counsel is "thoroughly competent," there is a "distinct possibility that the evidence presented would not have varied one iota had a qualified representative for each claim been present from the inception of the suit." 777 F.2d at 124.

The Court finds that Agnes Swayze, Mariella Laday, Thomas Trusky, and Muriel Tonacchio have been and will be adequate representatives for the consumer Track Two class.

**D. Associational Standing**

While the Court will allow the addition of the four individual consumer plaintiffs, class counsel has expressed the desire to add the organizational representatives as well. The question currently before the Court is whether the associations may still serve as class representatives for the purpose of settlement.

In the order granting preliminary approval of the Track Two settlement, the Court found that an agent or member of each of the associations listed above made a purchase or was reimbursed for one or more of the Class Drugs. (Docket No. 5426 at 5.) In a previous opinion on plaintiffs' initial motion to certify a class, the Court found that an association could not serve as a class representative for litigation purposes where the class seeks damages under Rule 23(b)(3). In re Pharm. Indus. Average

Wholesale Price Litig., 230 F.R.D. 61, 80 (D. Mass. 2005). In reaching that conclusion, the Court relied on the Second Circuit's opinion in Bano v. Union Carbine Corp., 361 F.3d 696 (2d Cir. 2004), in which the court declined to certify as a class representative in a damages action a grass-roots organization formed to help the victims of an explosion at a chemical manufacturing facility in India. Id. at 715. In Bano, the Second Circuit wrote:

If the involvement of individual members of an association is necessary, either because the substantive nature of the claim or the form of the relief sought requires their participation, we see no sound reason to allow the organization standing to press their claims, even where it seeks to do so as a putative class representative.

Id. at 715. Class counsel now argues that, for settlement purposes, the reasoning relied upon in Bano does not bar an association from serving as a class representative.

As a preliminary matter, to establish standing on behalf of its members, an association must show:

(a) its members would otherwise have standing to sue in their own right; (b) the interests it seeks to protect are germane to the organization's purpose; and (c) neither the claim asserted nor the relief requested requires the participation of individual members in the lawsuit.

United Food & Commercial Workers Union Local 751 v. Brown Group, Inc., 517 U.S. 544, 553 (1996) (quoting Hunt v. Washinton State Apple Advertising Comm'n, 432 U.S. 333, 343 (1977)). While the associations in this case easily meet the first two requirements,

the third poses a much more difficult question.

As the court in Bano recognized, the third requirement is a prudential consideration rather than a constitutional requirement for standing. 361 F.3d at 715 (citing Brown Group, 517 U.S. at 557 ("[T]he third prong of the associational standing test is best seen as focusing on . . . matters of administrative convenience and efficiency, not on elements of a case or controversy within the meaning of the Constitution.")). Federal courts have adopted prudential limits on standing in order "to avoid deciding questions of broad social import where no individual rights would be vindicated and to limit access to the federal courts to those litigants best suited to assert a particular claim." Phillips Petroleum Co. v. Shutts, 472 U.S. 797, 804 (1985). Accordingly, once an association has satisfied the first two prongs of the associational standing test, a court can be assured of "adversarial vigor in pursuing a claim for which member Article III standing exists," and the third question focuses on the "administrative convenience" of pursuing a case prosecuted by an associational representative. Brown Group, 517 U.S. at 556-57. The question for this Court, then, is whether the "individual participation" prong, which pertains to the administrative convenience of the Court, is applicable in a settlement context. The Court could find no case law on this particular point, and the parties have cited none.

In Amchem Products, Inc. v. Windsor, 521 U.S. 591 (1997),

the Supreme Court explained:

Confronted with a request for settlement-only class certification, a district court need not inquire whether the case, if tried, would present intractable management problems, see Fed. R. Civ. P. 23(b)(3)(D), for the proposal is that there be no trial. But other specifications of the Rule - those designed to protect absentees by blocking unwarranted or overbroad class definitions - demand undiluted, even heightened, attention in the settlement context. Such attention is of vital importance, for a court asked to certify a settlement class will lack the opportunity, present when a case is litigated, to adjust the class, informed by the proceedings as they unfold.

Id. at 620; see also In re Prudential Ins. Co. America Sales Practice Litigation Agent Actions, 148 F.3d 283, 308 (3d Cir. 1998) (recognizing that district courts need not address manageability concerns in certifying a class for settlement purposes). This Court's previous holding that organizations could not serve as class representatives in a 23(b)(3) action seeking damages was based on the fact that such a proceeding would require individualized proof of damages. Under Brown Group, this prohibition was required for prudential reasons of administrative convenience and efficiency, which are manageability concerns. However, as Amchem holds, "management problems" are less paramount in some classes certified for settlement purposes.

Here, because there is a formulaic basis for calculating individual class claims, proving individualized damages in a settlement context does not raise prudential management concerns. Therefore, the settlement status of this case satisfies the third

prong of the associational standing test.

The Court finds that the organizational class representatives in the Track Two case (Vermont Public Interest Research Group, Wisconsin Citizen Action, New York Statewide Senior Action Council, and Citizen Action of New York) have met the requirements for associational standing for the purposes of negotiating a settlement.

The proposed organizational representatives are typical and adequate representatives of the class. Indeed, organizational representatives with experience will provide more vigilant and consistent representation than individual representatives in a class action of old, sick, and dying class members. See Int'l Union, United Auto., Aerospace & Agr. Implement Workers of Am. (UAW) v. Brock, 477 U.S. 274, 289-90 (1986) ("[A]n organization suing to vindicate its members' interests can draw upon a pre-existing reservoir of expertise and capital. . . . The very forces that cause individuals to band together in an association will . . . provide some guarantee that the association will work to promote their interests."); 1 Albert Conte & Herbert B. Newberg, Newberg on Class Actions § 3:34 (4th ed. 2002) (noting that organizations may provide "enhanced psychological and bargaining power advantages" in negotiating settlements).

#### **ORDER**

For the foregoing reasons, the Court **ALLOWS** the Motion to

Add Individual and Associational Plaintiffs as Class

Representatives for the Track Two Settlement (Docket No. 7572).

/s/ PATTI B. SARIS  
PATTI B. SARIS  
United States District Judge

**Publisher Information**

**Note\* This page is not part of the opinion as entered by the court.**

**The docket information provided on this page is for the benefit  
of publishers of these opinions.**

1:01-cv-12257-PBS Citizens for Consume, et al v. Abbott Laboratories,, et al

Patti B. Saris, presiding

Marianne B. Bowler, referral

Date filed: 12/19/2001

Date of last filing: 08/30/2011

Attorneys

Jeffrey B. Aaronson Bell, repres Baxter International, Inc. TERMINATED: 08/30/2010 (Defendant)

Boyd & Lloyd 3 First enting

National Plaza 70 West

Madison Street, Suite 3200

Chicago, IL 60602-4207

Assigned: 06/03/2002

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Greg Abbott Office of the repres State of Texas (Consolidated Plaintiff)

Attorney General Capitol enting

Station PO Box 12548

Austin, TX 78711 Assigned:

12/27/2006 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Azure M. Abuirmeileh        repres Bristol-Myers Squibb Company    TERMINATED: 09/20/2009

Collora LLP 600 Atlantic    enting (Defendant)

Avenue 12th Flr. Boston,

MA 02210 617-371-1008

aabuirmeileh@collorallp.co

m Assigned: 12/01/2010

ATTORNEY TO BE

NOTICED

Oncology Therapeutics Network Corp.    TERMINATED: 09/20/2009

(Defendant)

Marc E. Ackerman Harris    repres Sandoz, Inc. (Defendant)

Beach LLP 1155 Avenue    enting

of the Americas New York,

NY 10036 212-819-8200

Assigned: 02/16/2007

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Philip F. Ackerman        repres Ethex Corporation    TERMINATED: 01/08/2010 (Defendant)

Sonnenschein, Nath &    enting

Rosenthal, LLP 233 South

Wacker Drive Sears Tower

Suite 7800 Chicago, IL

60606 312-876-8000

packerman@sonnenschein.

com Assigned: 04/23/2008

TERMINATED: 05/15/2008

LEAD ATTORNEY



ATTORNEY TO BE

NOTICED

Joseph G. Adams Snell & repres Pharmacia & Upjohn, Inc. (Defendant)

Wilmer LLP 1 Arizona enting

Center 400 E Van Buren

Phoenix, AZ 85004-2202

602-382-6207 602-382-

6070 (fax) Assigned:

06/21/2006 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Pharmacia Corporation TERMINATED: 02/22/2011 (Consolidated

Defendant)

Pamela Zorn Adams repres Gensia Sicor Pharmaceuticals, Inc. (Defendant)

Sherin and Lodgen LLP enting

101 Federal Street Boston,

MA 02110 617-646-2000

617-646-2222 (fax)

Assigned: 03/04/2004

TERMINATED: 03/20/2008

ATTORNEY TO BE

NOTICED

Sicor, Inc. TERMINATED: 11/10/2010 (Defendant)

Ivax Corporation TERMINATED: 08/10/2010 (Defendant)

Teva Pharmaceuticals USA, Inc. TERMINATED: 10/31/2008

(Defendant)

Ivax Pharmaceuticals, Inc. TERMINATED: 08/10/2010 (Defendant)

Kenneth W. Africano repres Allergan Inc. TERMINATED: 05/28/2008 (Consolidated Defendant)

Harter, Secrest Law firm enting

12 Fountain Plaza Suite

400 Buffalo, NY 14202-

2293 716-853-1616 716-

853-1617 (fax) Assigned:

02/16/2007 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Novo Nordisk Pharmaceuticals, Inc. TERMINATED: 05/28/2008

(Defendant)

Bayer Corporation TERMINATED: 04/14/2010 (Defendant)

Kevin N. Ainsworth Mintz, repres Eli Lilly and Company (Defendant)

Levin, Cohn, Ferris, enting

Glovsky and Popeo, P.C.

Chrysler Center 666 Third

Avenue New York, NY

10020 212-986-7200

Assigned: 02/16/2007

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Marjory P. Albee Berger & repres Ven-A-Care of the Florida Keys, Inc. (Plaintiff)

Montague, P.C. 1622 enting

Locust St. Philadelphia, PA

19103 215-875-3064 215-

875-4604 (fax)

malbee@bm.net Assigned:

10/29/2007 TERMINATED:

03/23/2010 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Ven-A-Care of the Florida Keys, Inc. (Consolidated Plaintiff)

Neil Alden Bowman and repres Baxter Healthcare Corporation TERMINATED: 12/16/2008

Brooke LLP 2901 North enting (Consolidated Defendant)

Central Avenue Suite 1600

Phoenix, AZ 85012

Assigned: 03/29/2006

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Kathryn Bale Allen Kirby repes Baxter International, Inc. TERMINATED: 08/30/2010 (Defendant)  
The City of New York and Captioned New York Counties (Plaintiff)

McInerney LLP 825 Third enting

Avenue New York, NY

10022 212-371-6600

kallen@kmlp.com

Assigned: 07/10/2008

LEAD ATTORNEY PRO

HAC VICE ATTORNEY TO

BE NOTICED

John R. Alphin Strom Law repes State of South Carolina (Consolidated Plaintiff)

Firm LLC 2110 Beltline enting

Bld., Suite A Columbia,

SC 29204 803-252-4800

803-252-4801 (fax)

jalphin@stromlaw.com

Assigned: 08/05/2011

ATTORNEY TO BE

NOTICED

Brooks A. Ames DLA Piper repes Cardinal Health, Inc (Interested Party)

Rudnick Gray Cary US LLP enting

26 th Floor 33 Arch Street

Boston, MA 02110-1447

617-406-6045 617-406-

6145 (fax)

brooks.ames@dlapiper.co

m Assigned: 07/11/2007

ATTORNEY TO BE

NOTICED

C. Jarrett Anderson repres Ven-A-Care of the Florida Keys, Inc. (Plaintiff)

Anderson LLC 1300 enting

Guadalupe Street Suite

103 Austin, TX 78701 512-

469-9191 512-532-0585

(fax) jarrett@anderson-

llc.com Assigned:

03/15/2007 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Joseph Angland White & repres Sandoz, Inc. (Defendant)

Case LLP Assigned: enting

05/28/2010 ATTORNEY TO

BE NOTICED

Anthony J. Anscombe repres Bristol-Myers Squibb Company TERMINATED: 09/20/2009

Sedgwick Detert Moran & enting (Defendant)

Arnold One North Wacker

Drive Suite 4200 Chicago,

IL 60606-2841 312-641-

9050

anthony.anscombe@sdma.

com Assigned: 12/20/2006

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Justin S. Antonipillai          repres Ethex Corporation TERMINATED: 01/08/2010 (Defendant)

Arnold & Porter, LLP 555    enting

Twelfth Street, NW

Washington, DC 20004

202-942-5066 202-942-

5999 (fax) Assigned:

03/21/2005 TERMINATED:

06/10/2008 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Melissa Aoyagi Davis Polk repres Astrazeneca Pharmaceuticals LP TERMINATED: 10/29/2010

& Wardwell 450 Lexington enting (Defendant)

Avenue New York, NY

10017 Assigned:

09/12/2006 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

P. Jeffrey Archibald          repres Commonwealth of Kentucky (Consolidated Plaintiff)

Archibald Consumer Law    enting

Office 1914 Monroe Street

Madison, WI 53711 608-

661-8855 Assigned:

09/05/2007 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

State of Idaho (Consolidated Plaintiff)

State of Illinois (Consolidated Plaintiff)  
State of South Carolina (Consolidated Plaintiff)  
Martin A. Aronson Morrill & repres Fujisawa Healthcare, Inc. TERMINATED: 02/25/2010 (Defendant)

Aronson 1 East Camelbackenting

Road Suite 340 Phoenix,

AZ 85012-1648 Assigned:

06/21/2006 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Fujisawa USA, Inc. TERMINATED: 02/25/2010 (Consolidated

Defendant)

Shoshanah V. Asnis New repres The City of New York and Captioned New York Counties (Plaintiff)

York State Office of the enting

Attorney General Litigation

Bureau The Capitol

Albany, NY 12224 518-

402-1224 Assigned:

05/13/2008 LEAD

ATTORNEY PRO HAC

VICE ATTORNEY TO BE

NOTICED

Daniel F. Attridge Kirkland repres B. Braun Medical Inc. TERMINATED: 12/16/2008 (Defendant)

& Ellis Suite 1200 655 enting

Fifteenth St.,N.W.

Washington, DC 20005

202-879-5012 202-879-

5200 (fax)

dattridge@kirkland.com

Assigned: 11/01/2002

TERMINATED: 04/27/2006

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Megan M. Auchincloss      B. Braun of America, Inc. TERMINATED: 10/27/2010 (Defendant)  
repres Purdue Pharma L.P. TERMINATED: 03/29/2010 (Defendant)

Morrison & Foerster LLP    enting

370 17th Street Suite 5200

Denver, CO 80202-5638

303-592-1500 303-592-

1510 (fax)

mauchincloss@mofo.com

Assigned: 11/29/2004

TERMINATED: 01/27/2005

LEAD ATTORNEY

Danielle Audette White &    repres Sandoz, Inc. (Defendant)

Case LLP Assigned:        enting

08/13/2010 ATTORNEY TO

BE NOTICED

Pamela J. Auerbach        repres Barr Laboratories, Inc. 2 Quaker Road P.O. Box 2900 Pomona, NY

Kirkland & Ellis LLP Suite    enting 10970-0519 TERMINATED: 08/10/2010 (Defendant)

1200 655 Fifteenth

St.,N.W. Washington, DC

20005 202-879-5000 202-

879-5200 (fax)

pauerbach@kirkland.com

Assigned: 02/16/2007

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Jennifer Aurora Sedgwick, repres Organon Pharmaceuticals USA, Inc. TERMINATED: 11/23/2010

Detert, Moran & Arnold,     enting (Defendant)

LLP 125 Broad Street 39th

Floor New York, NY 10004

212-422-0202 212-422-

0925 (fax) Assigned:

10/04/2005 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Gary L. Azorsky Berger &   repres Ven-A-Care of the Florida Keys, Inc. (Plaintiff)

Montague, PC 1622 Locustenting

Street Philadelphia, PA

19103 215-875-3000 215-

875-4604 (fax)

gazorsky@bm.net

Assigned: 09/02/2003

TERMINATED: 10/08/2010

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Violeta I Balan Mayer,     repres Johnson & Johnson TERMINATED: 10/27/2010 (Consolidated

Brown, Rowe & Maw LLP   enting Defendant)

71 South Wacker Drive

Chicago, IL 60606 312-

782-0600 Assigned:

12/20/2006 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Kathryn Bale Kirby,     repres State of Iowa (Consolidated Plaintiff)

McInerney & Squire, LLP   enting



830 Third Ave. 10th Floor

New York, NY 10022 212-

371-6600 212-751-2540

(fax) Assigned: 11/15/2007

ATTORNEY TO BE

NOTICED

Mitchell J. Banas, Jr. repres Biogen Idec, Inc. TERMINATED: 02/11/2009 (Consolidated

Jaeckle Fleischmann & enting Defendant)

Mugel LLP 12 Fountain

Plaza Buffalo, NY 14202

716-856-0600 716-856-

0432 (fax)

mbanas@jaeckle.com

Assigned: 02/16/2007

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Brian L. Bank White & repres Sandoz, Inc. (Defendant)

Case LLP 1155 Avenue of enting

the Americas New York,

NY 10036 212-819-8200

212-354-8113 (fax)

bbank@whitecase.com

Assigned: 06/21/2007

TERMINATED: 02/24/2011

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Susan Hughes Banning repres Neighborhood Health Plan, Inc. (Movant)

Hemenway & Barnes 60 enting

State Street Boston, MA

02109 617-557-9701 617-

227-7475 (fax)

sbanning@hembar.com

Assigned: 01/10/2006

TERMINATED: 06/02/2011

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Anita Bapooji Ryan repres TAP Pharmaceutical Products Inc (Defendant)

Goodwin Procter LLP enting

Exchange Place 53 State

Street Boston, MA 02109

617-570-1998 617-523-

1231 (fax)

abapooji@goodwinprocter.c

om Assigned: 04/09/2004

TERMINATED: 01/18/2007

ATTORNEY TO BE

NOTICED

Jason E. Baranski Morgan repres Pharmacia & Upjohn, Inc. (Defendant)

Lewis & Bockius, LLP 1701 enting

Market Street Philadelphia,

PA 19103-2921 Assigned:

06/25/2002 LEAD

ATTORNEY

Pharmacia Corporation TERMINATED: 02/22/2011 (Consolidated  
Defendant)

Scott A. Barbour McName, repres Teva Pharmaceuticals USA TERMINATED: 10/31/2008

Lochner, Titus & Williams enting (Consolidated Defendant)

75 State Street PO BOx

459 Albany, NY 12201-

0459 518-434-3136

Assigned: 02/16/2007

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Ivax Corporation TERMINATED: 08/10/2010 (Defendant)  
Steven F. Barley Hogan repres Amgen Inc. TERMINATED: 11/09/2009 (Defendant)

Lovells US LLP 100 enting

International Drive Suite

2000 Baltimore, MD 21202

410-659-2724 410-659-

2701 (fax)

steve.barley@hoganlovells.

com Assigned: 06/11/2002

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Jessica Vincent Barnett repres Astrazeneca Pharmaceuticals LP TERMINATED: 10/29/2010

Foley Hoag LLP 155 enting (Defendant)

Seaport Boulevard World

Trade Center West Boston,

MA 02210-2600 617-832-

3029 617-832-7000 (fax)

jbarnett@foleyhoag.com

Assigned: 10/28/2004

TERMINATED: 12/21/2007

ATTORNEY TO BE

NOTICED

Charles Barnhill, Jr. Miner, repres Commonwealth of Kentucky (Consolidated Plaintiff)

Barnhill & Galland, PC 44 enting

E. Mifflin Suite 803

Madison, WI 53703 608-

255-5200 608-255-5380

(fax) Assigned: 02/05/2007

ATTORNEY TO BE

NOTICED

State of Illinois (Consolidated Plaintiff)  
Christopher K. Barry-Smith repres State of Massachusetts (Consolidated Plaintiff)

Massachusetts Attorney enting

General's Office One

Ashburton Place Boston,

MA 02108 617-963-2539

617-727-5765 (fax)

chris.barry-

smith@state.ma.us

Assigned: 12/27/2006

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

David D. Bassett Kelley repres Mylan Pharmaceuticals, Inc. TERMINATED: 01/04/2011

Drye & Warren, LLP 101 enting (Defendant)

Park Avenue New York,

NY 10178 Assigned:

03/15/2010 LEAD

ATTORNEY PRO HAC

VICE ATTORNEY TO BE

NOTICED

Mylan, Inc. TERMINATED: 01/04/2011 (Defendant)

UDL Laboratories, Inc. TERMINATED: 01/04/2011 (Defendant)

S. Paul Battaglia Bond, repres Par Pharmaceutical, Inc. (Defendant)

Schoeneck & King PLLC enting

One Lincoln Center

Syracuse, NY 13202-1355

315-218-8000 315-218-

8100 (fax)

sbattaglia@bsk.com

Assigned: 02/16/2007

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Jon Steven Baughman repres Merck & Co., Inc. (Defendant)

Ropes & Gray LLP 700 enting

Twelfth Street, N.W. Suite

900 Washington, DC

20005-3948 202-508-4606

202-508-4650 (fax)

sbaughman@ropesgray.co

m Assigned: 06/21/2006

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Warrick Pharmaceuticals Corporation TERMINATED: 12/11/2009

(Consolidated Defendant)

Edwin Baum Proskauer, repres Biovail Pharmaceuticals, Inc. 700 Route 202/206 North Bridgewater,

Rose Law Firm 1585 enting NJ 08807 (Defendant)

Broadway New York, NY

10036 212-969-3175 212-

969-2900 (fax) Assigned:

02/16/2007 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

P. Ryan Beckett Butler, repres Eli Lilly and Company (Defendant)

Snow, O'Mara, Stevens & enting

Cannada PO Box 22567

Jackson, MS 39225-2567

601-948-5711 Assigned:

12/06/2006 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Rebecca Bedwell-Coll repres Constance Thompson (Plaintiff)

Mascone, Emblidge & enting

Quadra 180 Montgomery

Street 1240 San

Francisco, CA 94104 415-

362-3599 Assigned:

04/24/2003 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Stacy D. Belf Ropes & John B. Rice (Plaintiff)  
repres Merck & Co., Inc. (Defendant)

Gray LLP 1 Metro Center enting

700 12th St. NW Suite 900

Washington, DC 20016

202-508-4692 Assigned:

06/21/2006 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

David E. Bell Crowell & repres Purepac Pharmaceutical Co. (Defendant)

Moring LLP 1001 enting

Pennsylvania Ave, NW

Washington, DC 20004

202-624-2500

dbell@crowell.com

Assigned: 02/25/2011

ATTORNEY TO BE

NOTICED

Terriane Benedetto Kline repres International Union of Operating Engineers, Local No. 68 Welfare

& Specter 1525 Locust enting Fund (Consolidated Plaintiff)

Street 19th Floor

Philadelphia, PA 19102

Assigned: 04/19/2005

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Susan Aaronson Kline & Specter, P.C. 1525 Locust Street

Philadelphia, PA 19102 215-772-1000 215-735-0957 (fax)

terri.benedetto@klinespecter.com (Plaintiff)

Daniel J. Bennett Ropes & repres Merck & Co., Inc. (Defendant)

Gray - MA Prudential enting

Tower 800 Boylston Street

Boston, MA 02199-3600

617-951-7715 617-951-

7050 (fax)

daniel.bennett@ropesgray.

com Assigned: 05/21/2007

ATTORNEY TO BE

NOTICED

Warrick Pharmaceuticals Corporation TERMINATED: 12/11/2009

(Consolidated Defendant)

Alexander L. Berg Kirkland repres Teva Pharmaceuticals USA TERMINATED: 10/31/2008

& Ellis LLP 655 Fifteenth enting (Consolidated Defendant)

Street, N.W. Washington,

DC 20005 202-879-5000

Assigned: 03/10/2008

LEAD ATTORNEY PRO

HAC VICE ATTORNEY TO

BE NOTICED

Teva Pharmaceuticals USA, Inc. TERMINATED: 10/31/2008

(Defendant)

Ivax Corporation TERMINATED: 08/10/2010 (Defendant)

Sicor, Inc. TERMINATED: 11/10/2010 (Defendant)

Curtis Bergen Bowman repres Baxter Healthcare Corporation TERMINATED: 12/16/2008

and Brooke LLP 2901 enting (Consolidated Defendant)

North Central Avenue

Suite 1600 Phoenix, AZ

85012 Assigned:

03/29/2006 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Baxter International, Inc. TERMINATED: 08/30/2010 (Defendant)

Elizabeth M. Bergen repres TAP Pharmaceutical Products Inc (Defendant)

Gibson, McAskill Law Firm enting

69 Delaware Avenue Suite



900 Chemical Bank

Building Buffalo, NY

14202-3866 716-856-4200

716-856-4200 (fax)

Assigned: 02/16/2007

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Lawrence D. Berger                      Abbott Laboratories, Inc. TERMINATED: 12/16/2008 (Defendant)  
repres Immunex Corporation TERMINATED: 01/25/2007 (Defendant)

Ballard, Spahr, Andrews & enting

Ingersoll, LLP 1735 Market

Street 51st Floor

Philadelphia, PA 19103

215-864-8119 215-864-

9509 (fax) Assigned:

01/30/2007 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Dawn M. Berhony                      repres Organon USA (Defendant)

Sedgwick, Detert, Moran & enting

Arnold LLP 125 Broad

Street 39th Floor New

York, NY 10004 212-422-

0202 212-422-0925 (fax)

Assigned: 11/21/2007

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Eric P. Berlin Jones Day repres Abbott Laboratories, Inc. TERMINATED: 12/16/2008 (Defendant)

77 West Wacker Drive enting

Chicago, IL 60601-1692

312-782-3939 312-782-

8585 (fax) Assigned:

06/04/2008 LEAD

ATTORNEY PRO HAC

VICE ATTORNEY TO BE

NOTICED

Mark A. Berman repres Reliant Pharmaceuticals, LLC (Defendant)

HARTMANN DOHERTY enting

ROSA & BERMAN, LLC

126 State Street

Hackensack, NJ 07601

201-441-9056 201-441-

9435 (fax)

mberman@hartmanndohert

y.com Assigned:

09/16/2003 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Berlax Laboratories, Inc. TERMINATED: 05/28/2008 (Defendant)  
Steve W. Berman Hagens repres All Plaintiffs (Plaintiff)

Berman Sobol Shapiro LLP enting

Suite 3300 1918 Eighth

Avenue Seattle, WA 98101

206-623-7292 206-623-

0594 (fax)

steve@hbsslaw.com

Assigned: 05/03/2004 PRO

HAC VICE ATTORNEY TO

BE NOTICED

Arizona, State of (Consolidated Plaintiff)  
Government Employees Hospital Association (Consolidated Plaintiff)  
Pipefitters Local 537 Trust Funds (Plaintiff)  
State of Arizona (Consolidated Plaintiff)  
State of Montana (Plaintiff)  
State of Nevada (Plaintiff)  
State of Nevada/State of Montana (Plaintiff)  
Harold Bean (Plaintiff)  
Shirley Geller (Consolidated Plaintiff)  
Astrazeneca Pharmaceuticals LP TERMINATED: 10/29/2010

(Defendant)

Health Care For All (Plaintiff)

David J. Bershad Milberg repes Citizens for Consumer Justice (Plaintiff)

Weiss Bershad Hynes & enting

Lerach LLP One

Pennsylvania Plaza 49th

Floor New York, NY 10119

212-594-5300 Assigned:

12/19/2001 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Colorado Progressive Coalition (Plaintiff)  
Congress of California Seniors (Plaintiff)  
Florida Alliance for Retired Americans (Plaintiff)  
Health Care For All (Plaintiff)  
Massachusetts Senior Action Council (Plaintiff)  
Masspirg (Plaintiff)  
Minnesota Senior Federation (Plaintiff)  
New Jersey Citizen Action (Plaintiff)  
New York State Wide Senior Action Council (Plaintiff)  
Pennsylvania Alliance For Retired Americans (Plaintiff)  
Vermont Public Interest Research Group (Plaintiff)  
West Virginia Citizen Action (Plaintiff)  
Wisconsin Citizen Action (Plaintiff)  
Citizen Action of New York (Plaintiff)  
Connecticut Citizen Action Group (Plaintiff)  
Gray Panthers of Sacramento (Plaintiff)  
Health Action of New Mexico (Plaintiff)  
Maine Consumers for Affordable Health Care (Plaintiff)

North Carolina Fair Share (Plaintiff)  
Oregon Health Action Campaign (Plaintiff)  
Oregon State Public Interest Research Group (Plaintiff)  
United Senior Action of Indiana, Inc. (Plaintiff)  
Betty Sicher (Plaintiff)  
Jack Douglas (Plaintiff)  
Joan S. Lee (Plaintiff)  
John Bennett (Plaintiff)  
Pearl Munic (Plaintiff)  
Sue Miles (Plaintiff)

Adelina O. Berumen          repres State of California (Plaintiff)

California Department of    enting

Justice Bureau of Medi-Cal

Fraud 1455 Frazee Road

Suite 315 San Diego, CA

92108-4304 619-688-6753

619-688-4200 (fax)

adelina.berumen@doj.ca.g

ov Assigned: 03/23/2005

TERMINATED: 09/12/2006

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Lara A. Berwanger White & repres Sandoz, Inc. (Defendant)

Case LLP 1155 Avenue of enting

the Americas New York,

NY 10036 212-819-8200

212-354-8113 (fax)

lberwanger@whitecase.co

m Assigned: 07/19/2007

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Aimee E. Bierman                    repres Aventis Pharma TERMINATED: 10/26/2004 (Consolidated  
Kirkpatrick & Lockhart            enting Defendant)

Preston Gates Ellis LLP

State Street Financial

Center One Lincoln

Boston, MA 02111 617-

261-3100 617-261-3175

(fax)

aimee.bierman@klgates.co

m Assigned: 04/09/2004

TERMINATED: 03/31/2009

Sanofi-Synthelabo, Inc. TERMINATED: 10/26/2004 (Defendant)  
Hoescht Marion Roussel, Inc. TERMINATED: 02/19/2008

(Defendant)

Aventis Pharmaceuticals Inc. TERMINATED: 02/20/2008

(Defendant)

Aventis Behring LLC TERMINATED: 11/21/2008 (Consolidated

Defendant)

Z.L.B. BEHRING TERMINATED: 12/16/2008 (Intervenor Defendant)

Thomas M. Biesty White & repres Sandoz, Inc. (Defendant)

Case LLP 1155 Avenue of enting

the Americas New York,

NY 10036 212-819-8200

212-354-8113 (fax)

Assigned: 08/02/2007

TERMINATED: 06/25/2008

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Brandon L. Bigelow                    repres Takeda Pharmaceuticals North America, Inc. TERMINATED:

Bingham McCutchen LLP - enting 05/29/2008 (Defendant)

MA One Federal Street

Boston, MA 02110-1726

617-951-8000

brandon.bigelow@bingham.

com Assigned: 05/09/2005

ATTORNEY TO BE

NOTICED

Takeda Pharmaceutical Company, Limited TERMINATED:

05/28/2008 (Consolidated Defendant)

Scott A. Birnbaum repres Ethex Corporation TERMINATED: 01/08/2010 (Defendant)

Birnbaum & Godkin, LLP enting

280 Summer Street

Boston, MA 02210-1108

617-307-6100 617-307-

6101 (fax)

birnbaum@birnbaumgodkin

.com Assigned: 04/22/2008

TERMINATED: 02/02/2010

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Ethex TERMINATED: 04/28/2010 (Consolidated Defendant)

Sheila L. Birnbaum repres Merck & Co., Inc. (Defendant)

Skadden Arps Slate enting

Meagher & Flom LLP Four

Times Square New York,

NY 10036-6522 212-735-

3000 212-735-2000 (fax)

sbirnbau@skadden.com

Assigned: 02/17/2005

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Warrick Pharmaceuticals Corporation TERMINATED: 12/11/2009

(Consolidated Defendant)

Charles John Biro Sidley repes Johnson & Johnson TERMINATED: 10/27/2010 (Consolidated

Autsin LLP One South enting Defendant)

Dearborn Street Chicago,

IL 60603 312-853-7000

Assigned: 12/26/2006

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Ortho-McNeil Pharmaceutical, Inc. TERMINATED: 12/17/2010

(Defendant)

Donald Wayne Bivens repes Dey Inc. TERMINATED: 02/25/2010 (Defendant)

Meyer Hendricks & Bivens enting

PA 3003 North Central

Avenue Suite 1200

Phoenix, AZ 85012 602-

604-2200 Assigned:

06/21/2006 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Steven E. Bizar Buchanan repes AmerisourceBergen Corporation (Unknown)

Ingersoll, P.C. 1835 Marketenting

Street 11 Penn Center,

14th Floor Philadelphia, PA

19103-2985 Assigned:

04/19/2006 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Larry Black 7039 repres Ven-A-Care of the Florida Keys, Inc. (Plaintiff)

Comanche Trail Austin, TX enting

78732 512-402-1745

Assigned: 02/13/2008

LEAD ATTORNEY PRO

HAC VICE ATTORNEY TO

BE NOTICED

Rex Blackburn Blackburn repres Abbott Laboratories, Inc. TERMINATED: 12/16/2008 (Defendant)

& Jones PO Box 7808 enting

Boise, ID 83707 208-489-

8989 Assigned: 05/08/2007

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Sam B. Blair, Jr. Baker, repres King Pharmaceuticals, Inc. (Defendant)

Donelson, Bearman, enting

Caldwell & Berkowitz First

Tennessee Building 165

Madison Ave. Suite 2000

Memphis, TN 38103 901-

526-2000 901-577-2000

(fax)

sblair@bakerdonelson.com

Assigned: 04/21/2005

LEAD ATTORNEY

ATTORNEY TO BE



NOTICED

Monarch Pharmaceuticals, Inc. (Defendant)  
Lynn M. Blake Freidman, repres Merck & Co., Inc. (Defendant)

Hirschen Law Firm PO Boxenting

1041 100 Great Oaks Blvd.

Albany, NY 12203 518-

377-2225 518-377-2247

(fax) Assigned: 02/16/2007

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Genzyme Corporation TERMINATED: 01/06/2006 (Defendant)  
Eisai, Inc. TERMINATED: 11/17/2008 (Consolidated Defendant)  
Warrick Pharmaceuticals Corporation TERMINATED: 12/11/2009

(Consolidated Defendant)  
Robert P. Blood Goodwin repres TAP Pharmaceutical Products Inc (Defendant)

Procter LLP Exchange enting

Place 53 State Street

Boston, MA 02109 617-

570-1000 617-523-1231

(fax) Assigned: 01/18/2007

TERMINATED: 06/27/2007

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Elise M. Bloom Proskauer repres Biovail Pharmaceuticals, Inc. 700 Route 202/206 North Bridgewater,

Rose LLP - NY 1585 enting NJ 08807 (Defendant)

Broadway New York, NY

10036-8299 212-969-3410

212-969-2900 (fax)

ebloom@proskauer.com

Assigned: 02/16/2007

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Jack B. Blumenfeld Morris, repres Astrazeneca PLC (Consolidated Defendant)

Nichols, Arsht, & Tunnell enting

1201 North Market Street

Wilmington, DE 19899-

1347 302-658-9200

Assigned: 10/25/2002

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Thomas L. Boeder Perkins repres Immunex Corporation TERMINATED: 01/25/2007 (Defendant)

Coie 1201 Third Avenue, enting

40th Floor Seattle, WA

98101-3099 206-583-8575

Assigned: 06/03/2002

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Anthony Bolognese repres United Food & Commercial Workers Unions and Employers Midest

Bolognese & Associates enting Health Benefits Fund (Consolidated Plaintiff)

Suite 650 One Penn

Center 1617 JFK Blvd.

Philadelphia, PA 19103

Assigned: 05/31/2002

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Thomas J. Bone, III Foley repres Astrazeneca Pharmaceuticals LP TERMINATED: 10/29/2010

Hoag LLP 155 Seaport enting (Defendant)

Boulevard Seaport World

Trade Center West Boston,

MA 02210 617-832-1204

617-832-7000 (fax)

jbone@foleyhoag.com

Assigned: 12/10/2007

ATTORNEY TO BE

NOTICED

Mylan Pharmaceuticals, Inc. TERMINATED: 01/04/2011

(Defendant)

Mylan, Inc. TERMINATED: 01/04/2011 (Defendant)

UDL Laboratories, Inc. TERMINATED: 01/04/2011 (Defendant)

Nancy M Bonnell 1275 repres Action Alliance of Senior Citizens of Greater Philadelphia

West Washington Phoenix,enting (Consolidated Plaintiff)

AZ 85007 Assigned:

04/17/2007 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

All Plaintiffs (Plaintiff)

Arizona, State of (Consolidated Plaintiff)

Carpenters & Millwrights of Houston and Vicinity Welfare Trust Fund,

Board of Trustees, Individually and on behalf of all others similarly

situated (Consolidated Plaintiff)

Citizens for Consumer Justice (Plaintiff)

Colorado Progressive Coalition (Plaintiff)

Commonwealth of Kentucky (Consolidated Plaintiff)

Commonwealth of Pennsylvania (Consolidated Plaintiff)

Congress of California Seniors (Plaintiff)

Connecticut Citizen Action Group (Plaintiff)

County of Chautauqua (Consolidated Plaintiff)

County of Chenango (Consolidated Plaintiff)

County of Cortland (Consolidated Plaintiff)

County of Dutchess (Consolidated Plaintiff)

County of Lewis (Consolidated Plaintiff)  
 County of Nassau (Consolidated Plaintiff)  
 County of Onondaga (Consolidated Plaintiff)  
 County of Ontario (Consolidated Plaintiff)  
 County of Orleans (Consolidated Plaintiff)  
 County of Oswego (Consolidated Plaintiff)  
 County of Rockland (Consolidated Plaintiff)  
 County of Schenectady (Consolidated Plaintiff)  
 County of Schuyler (Consolidated Plaintiff)  
 County of Seneca (Consolidated Plaintiff)  
 County of Westchester (Consolidated Plaintiff)  
 County of Wyoming (Consolidated Plaintiff)  
 Essex County (Consolidated Plaintiff)  
 Florida Alliance for Retired Americans (Plaintiff)  
 Government Employees Hospital Association (Consolidated Plaintiff)  
 Gray Panthers of Sacramento (Plaintiff)  
 Health Action of New Mexico (Plaintiff)  
 Health Care For All (Plaintiff)  
 International Union of Operating Engineers, Local No. 68 Welfare  
 Fund (Consolidated Plaintiff)  
 Maine Consumers for Affordable Health Care (Plaintiff)  
 Massachusetts Senior Action Council (Plaintiff)  
 Masspirg (Plaintiff)  
 Minnesota Senior Federation (Plaintiff)  
 National Automatic Sprinkler Industry Welfare Fund (Intervenor  
 Plaintiff)  
 New Jersey Citizen Action (Plaintiff)  
 New York State Wide Senior Action Council (Plaintiff)  
 North Carolina Fair Share (Plaintiff)  
 Oregon Health Action Campaign (Plaintiff)  
 Oregon State Public Interest Research Group (Plaintiff)  
 Pennsylvania Alliance For Retired Americans (Plaintiff)  
 Pipefitters Local 537 Trust Funds (Plaintiff)  
 Rice & Thompson (Plaintiff)  
 State of Arizona (Consolidated Plaintiff)  
 State of California (Plaintiff)  
 State of Connecticut (Plaintiff)  
 State of Florida (Plaintiff)  
 State of Mississippi (Consolidated Plaintiff)  
 State of Montana (Plaintiff)  
 State of Nevada (Plaintiff)  
 State of Nevada/State of Montana (Plaintiff)  
 State of New York (Plaintiff)  
 State of Ohio (Consolidated Plaintiff)  
 State of South Carolina (Consolidated Plaintiff)  
 Suffolk County (NY) (Plaintiff)  
 The City of New York and Captioned New York Counties (Plaintiff)  
 The County of Columbia (Consolidated Plaintiff)  
 The County of Erie (Consolidated Plaintiff)  
 The County of Ulster (Consolidated Plaintiff)  
 The People of the State of Illinois (Plaintiff)

Twin Cities Baker Workers Health & Welfare Fund (Consolidated  
Plaintiff)  
United Food & Commercial Workers Unions and Employers Midwest

Health Benefits Fund (Consolidated Plaintiff)  
United Senior Action of Indiana, Inc. (Plaintiff)  
United States, ex rel. (Consolidated Plaintiff)  
Ven-A-Care of the Florida Keys, Inc. (Plaintiff)  
Vermont Public Interest Research Group (Plaintiff)  
West Virginia Citizen Action (Plaintiff)  
Wisconsin Citizen Action (Plaintiff)  
Betty Sicher (Plaintiff)  
Constance Thompson (Plaintiff)  
Edward West (Consolidated Plaintiff)  
Harold Bean (Plaintiff)  
Henry D. McMaster (Consolidated Plaintiff)  
Jack Douglas (Plaintiff)  
Joan S. Lee (Plaintiff)  
John Bennett (Plaintiff)  
John V. Digel (Consolidated Plaintiff)  
John B. Rice (Plaintiff)  
Kimberly K. Hoover (Intervenor Plaintiff)  
Leroy Townsend (Consolidated Plaintiff)  
Pearl Munic (Plaintiff)  
Robert J. Swanston (Plaintiff)  
Roberta S. Starks (Intervenor Plaintiff)  
Ronald E. Turner (Consolidated Plaintiff)  
Shirley Geller (Consolidated Plaintiff)  
Sue Miles (Plaintiff)  
T. Mark Jones (Plaintiff)  
Zachary T. Bentley (Consolidated Plaintiff)  
Abbott Laboratories, Inc. TERMINATED: 12/16/2008 (Defendant)  
The City of New York 100 Church Street Room 3-162 New York,

NY 10007 212-788-1007 (Plaintiff)  
Susan Aaronson Kline & Specter, P.C. 1525 Locust Street

Philadelphia, PA 19102 215-772-1000 215-735-0957 (fax)

terri.benedetto@klinespecter.com (Plaintiff)  
Kline & Specter, P.C. Kline & Specter, P.C. 1525 Locust Street

19th Floor Philadelphia, PA 19102 215-772-1000 215-735-0957

(fax) shanin.specter@klinespecter.com (All Plaintiffs)  
Esquire Donald E. Haviland, Jr. The Haviland Law Firm, LLC 740

S. Third Street Third Floor Philadelphia, PA 19147 215-609-4661

215-392-4400 (fax) haviland@havilandlaw.com (Plaintiff)

Andrew T. Boone Williams repres Par Pharmaceutical Companies, Inc. (Consolidated Defendant)

& Connolly LLP 725 enting

Twelfth Street, N.W.

Washington, DC 20005

202-434-5786 202-434-

5029 (fax)

aboone@wc.com Assigned:

11/29/2007 LEAD

ATTORNEY ATTORNEY

TO BE NOTICED

Par Pharmaceutical, Inc. (Defendant)  
Laural S. Boone White & repres Sandoz, Inc. (Defendant)

Case LLP 1155 Avenue of enting

the Americas New York,

NY 10036 212-819-8200

212-354-8113 (fax)

lboone@whitecase.com

Assigned: 09/11/2008

TERMINATED: 01/27/2009

LEAD ATTORNEY PRO

HAC VICE ATTORNEY TO

BE NOTICED

Lisa W. Borden Baker, repres King Pharmaceuticals, Inc. (Defendant)

Donelson, Bearman, enting

Caldwell & Berkowitz, P.C.

Wachovia Tower 420 20th

Street North Suite 1600

Birmingham, AL 35203

205-328-0480 205-488-

3803 (fax)

lborden@bakerdonelson.co

m Assigned: 04/23/2009

LEAD ATTORNEY PRO

HAC VICE ATTORNEY TO

BE NOTICED

Elissa F. Borges Ober,      King Research and Development (Consolidated Defendant)  
   Monarch Pharmaceuticals, Inc. (Defendant)  
repres Wyeth TERMINATED: 02/22/2011 (Defendant)

Kaler, Grimes & Shriver A enting

Professional Corporation

120 East Baltimore Street

Baltimore, MD 21202-1643

410-685-1120 410-547-

0699 (fax)

efborges@ober.com

Assigned: 03/13/2008

LEAD ATTORNEY PRO

HAC VICE ATTORNEY TO

BE NOTICED

Neville H. Boschert      repres Teva Pharmaceuticals USA, Inc. TERMINATED: 10/31/2008

Watkins, Ludlam, Winter& enting (Defendant)

Stennis, P.A., 63 North

State street Jackson, MS

39202-0427 601-949-4703

601-949-4804 (fax)

nboschert@watkinsludlam.c

om Assigned: 12/06/2006

TERMINATED: 10/09/2007

LEAD ATTORNEY

ATTORNEY TO BE

NOTICED

Ivax Pharmaceuticals, Inc. TERMINATED: 08/10/2010 (Defendant)  
Sicor, Inc. TERMINATED: 11/10/2010 (Defendant)

Michael P Boudett Foley Hoag LLP 155 Seaport Boulevard Boston, MA 02210-2600 617-832-1180

617-832-7000 (fax) mboudett@foleyhoag.com Assigned: 09/29/2006 TERMINATED: 09/01/2010

ATTORNEY TO BE